Product Description
Mechanisms of Action: PDE5 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Korea
Approved Indications: None
Known Adverse Events: None
Company: SK Chemicals
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Erectile Dysfunction
Phase 1: Erectile Dysfunction|Healthy Volunteers|Kidney Diseases|Hypertension
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| SID123_DDI_I_2014 | P1 |
Completed |
Healthy Volunteers |
2014-12-01 |
|
| SID123_DDI_I_2013 | P1 |
Completed |
Healthy Volunteers |
2013-11-01 |
|
| SK3530_RI_I | P1 |
Completed |
Kidney Diseases |
2011-12-01 |
|
| SK3530_AMD_I_2007 | P1 |
Completed |
Hypertension |
2009-05-01 |